Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 92

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Inguinal hernia+1

Not recruiting

Study on the Effectiveness and Safety of Chloroprocaine Hydrochloride for Children Undergoing Flat Foot or Inguinal Hernia Surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Codeine Phosphate
  • Sponsor:Sintetica S.A.

Astrocytoma malignant+2

Not recruiting

Study on the Safety of Aminolevulinic Acid with Ultrasound Therapy for Patients with Newly Diagnosed High-Grade Glioma Before Surgery and Standard Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aminolevulinic Acid Hydrochloride
  • Sponsor:Universitaet Muenster

Fabry's disease

Not recruiting

Study on Long-Term Safety of Oral Lucerastat for Adults with Fabry Disease

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lucerastat
  • Sponsor:Idorsia Pharmaceuticals Ltd.

Glioblastoma

Not recruiting

Study on WT1 LAMP mRNA DC and Temozolomide for Patients with Newly Diagnosed Glioblastoma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:WT1 LAMP mRNA DC
  • Sponsor:Antwerp University Hospital

Brain neoplasm

Not recruiting

Safety Study of 5-Aminolevulinic Acid for Brain Tumor Surgery in Children and Adolescents

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Aminolevulinic Acid Hydrochloride
  • Sponsor:Universitaet Muenster

Central nervous system lymphoma

Not recruiting

Study on De-escalated Induction Therapy with Methotrexate, Cytarabine, Thiotepa, and Rituximab for Newly Diagnosed Primary CNS Lymphoma Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Klinikum Der Landeshauptstadt Stuttgart gKAöR

Amyotrophic lateral sclerosis

Not recruiting

Study of Lithium Treatment for Patients with Amyotrophic Lateral Sclerosis (ALS) to Evaluate Survival Rate

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Stichting TRICALS Foundation

Central nervous system lymphoma

Not recruiting

Study on [18F]-Fludarabine and Gadoteric Acid for Imaging in Patients with Newly Diagnosed Primary CNS Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gadoteric Acid
  • Sponsor:Assistance Publique Hopitaux De Paris

Ischaemic stroke

Not recruiting

Study on Blood Pressure Management with Urapidil, Phenylephrine, and Labetalol for Patients with Acute Ischemic Stroke After Endovascular Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Urapidil
  • Sponsor:Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau

Dementia Alzheimer's type

Not recruiting

Study on the Effects of ALZ-801 in Patients Aged 50-80 with Early Alzheimer's Disease and APOE4 Genotype

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Valiltramiprosate
  • Sponsor:Alzheon Inc.

Fragile X syndrome

Not recruiting

Study on the Effects and Safety of ZYN002 Gel for Children, Adolescents, and Young Adults with Fragile X Syndrome

Investigational
Countries:IrelandIreland
  • Participants:0–17 years · 18–64 years
  • Substances:Cannabidiol
  • Sponsor:Harmony Biosciences Management Inc.

Dystonic tremor

Not recruiting

Study on Botulinum Toxin Type A for Arm Tremor in Patients with Dystonia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A - Haemagglutinin Complex
  • Sponsor:Stichting Radboud universitair medisch centrum

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.